The Lancet Diabetes & Endocrinology Published Saturday August 22, 2026 the Full EECOH-2 Phase 3 Trial Results for Xianweida's Ecnoglutide (XW003), a First-in-Class cAMP-Biased GLP-1 Receptor Agonist That Preferentially Activates the cAMP Signaling Pathway Over β-Arrestin Recruitment; The 52-Week Open-Label Non-Inferiority Trial Across 52 Chinese Hospitals Compared Ecnoglutide (0.6 mg or 1.2 mg Once Weekly Subcutaneous Injection) Against Dulaglutide 1.5 mg in Adults With Type 2 Diabetes and Elevated Glucose Concentrations on Metformin Monotherapy; Both Ecnoglutide Doses Met the Non-Inferiority Endpoint on HbA1c Reduction, and Both Were Well Tolerated; The Biased-Agonism Concept (Selective Signaling Pathway Activation Rather Than Full Receptor Engagement) Has the Potential to Separate Efficacy From Side Effects in the GLP-1 Class
The Lancet Diabetes & Endocrinology published Saturday August 22, 2026 the full EECOH-2 Phase 3 trial results for Xianweida's ecnoglutide (XW003), a first-in-class cAMP-biased GLP-1 receptor agonist. Mechanism: ecnoglutide preferentially activates the cAMP intracellular signaling pathway over β-arrestin recruitment when it binds the GLP-1 receptor. This biased-agonism concept selects one downstream signaling arm over the other, with the theoretical potential to separate the therapeutic effects (glucose lowering via cAMP-mediated insulin secretion) from the side-effect burden (some of which may be β-arrestin-mediated). Trial design: 52-week open-label non-inferiority Phase 3 across 52 Chinese hospitals. Adults aged 18-75 years with BMI 20-35 kg/m2, type 2 diabetes diagnosis, and elevated glucose concentrations on metformin monotherapy. Randomized to subcutaneous ecnoglutide 0.6 mg or 1.2 mg once weekly, or dulaglutide 1.5 mg once weekly (active comparator). Primary results: both ecnoglutide doses met the non-inferiority endpoint on HbA1c reduction versus dulaglutide 1.5 mg. Both doses were well tolerated with a safety profile broadly consistent with the GLP-1 receptor agonist class. Ecnoglutide is the first global cAMP-biased GLP-1 receptor agonist to reach Phase 3 publication. The biased-agonism approach could inform next-generation GLP-1 drug design and offers a differentiated tolerability profile if the concept holds in larger populations.